Colivelin is a synthetic chimeric peptide engineered by fusing Activity-Dependent Neurotrophic Factor (ADNF) with the neuroprotective peptide Humanin. This unique hybrid structure was designed to exhibit synergistic neuroprotective activity, capitalising on complementary mechanisms of action from both parent peptides. Colivelin has demonstrated potent inhibition of neuronal apoptosis in preclinical research models, acting via the STAT3 signalling pathway and through modulation of intracellular calcium dysregulation associated with neurodegeneration.
In laboratory studies, Colivelin has been investigated for its capacity to rescue neurons from amyloid-beta-induced toxicity, a hallmark mechanism in Alzheimer’s disease research. It has also shown promise in models of ischaemic neuronal injury and other neurodegenerative conditions, making it a valuable tool in academic and pharmaceutical research settings.
This product is supplied as 10mg of lyophilised powder with a purity exceeding 98% as confirmed by HPLC analysis. Molecular formula: C₁₄₉H₂₅₂N₄₄O₄₃S. Molecular weight: approximately 3,323.9 g/mol. CAS number: 867021-83-8. Recommended storage is at -20°C, protected from moisture and repeated freeze-thaw cycles, to maintain peptide integrity over time.
Molecular Formula
C₁₄₉H₂₅₂N₄₄O₄₃S
Molecular Weight
3323.9 g/mol
Purity
>98%
CAS Number
867021-83-8
Form
Lyophilised Powder
Research Applications
Neuroprotection research, Alzheimer’s disease models, neuronal apoptosis inhibition, STAT3 signalling studies, ischaemic injury models, neurodegenerative disease research
For research purposes only. Not for human use.
Reviews
There are no reviews yet.